These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 24011176)

  • 1. Gender-dependent differences in uridine 5'-diphospho-glucuronosyltransferase have implications in metabolism and clearance of xenobiotics.
    Liu W; Kulkarni K; Hu M
    Expert Opin Drug Metab Toxicol; 2013 Dec; 9(12):1555-69. PubMed ID: 24011176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential.
    Miners JO; Mackenzie PI; Knights KM
    Drug Metab Rev; 2010 Feb; 42(1):196-208. PubMed ID: 19795925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous quantification of the abundance of several cytochrome P450 and uridine 5'-diphospho-glucuronosyltransferase enzymes in human liver microsomes using multiplexed targeted proteomics.
    Achour B; Russell MR; Barber J; Rostami-Hodjegan A
    Drug Metab Dispos; 2014 Apr; 42(4):500-10. PubMed ID: 24408517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenomics of human uridine diphospho-glucuronosyltransferases and clinical implications.
    Guillemette C; Lévesque É; Rouleau M
    Clin Pharmacol Ther; 2014 Sep; 96(3):324-39. PubMed ID: 24922307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coupling of UDP-glucuronosyltransferases and multidrug resistance-associated proteins is responsible for the intestinal disposition and poor bioavailability of emodin.
    Liu W; Feng Q; Li Y; Ye L; Hu M; Liu Z
    Toxicol Appl Pharmacol; 2012 Dec; 265(3):316-24. PubMed ID: 22982073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intestinal UGTs as potential modifiers of pharmacokinetics and biological responses to drugs and xenobiotics.
    Ritter JK
    Expert Opin Drug Metab Toxicol; 2007 Feb; 3(1):93-107. PubMed ID: 17269897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topological aspects of oligomeric UDP-glucuronosyltransferases in endoplasmic reticulum membranes: advances and open questions.
    Bock KW; Köhle C
    Biochem Pharmacol; 2009 May; 77(9):1458-65. PubMed ID: 19150343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in the pharmacokinetics of peroxisome proliferator-activated receptor agonists in genetically obese Zucker and sprague-dawley rats: implications of decreased glucuronidation in obese Zucker rats.
    Kim MS; Wang S; Shen Z; Kochansky CJ; Strauss JR; Franklin RB; Vincent SH
    Drug Metab Dispos; 2004 Sep; 32(9):909-14. PubMed ID: 15319330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [UDP-glucuronyltransferases in detoxification and activation metabolism of endogenous compounds and xenobiotics].
    Fedejko B; Mazerska Z
    Postepy Biochem; 2011; 57(1):49-62. PubMed ID: 21735820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucuronidation of curcuminoids by human microsomal and recombinant UDP-glucuronosyltransferases.
    Hoehle SI; Pfeiffer E; Metzler M
    Mol Nutr Food Res; 2007 Aug; 51(8):932-8. PubMed ID: 17628876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolism of the c-Fos/activator protein-1 inhibitor T-5224 by multiple human UDP-glucuronosyltransferase isoforms.
    Uchihashi S; Fukumoto H; Onoda M; Hayakawa H; Ikushiro S; Sakaki T
    Drug Metab Dispos; 2011 May; 39(5):803-13. PubMed ID: 21346002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism.
    Picard N; Ratanasavanh D; Prémaud A; Le Meur Y; Marquet P
    Drug Metab Dispos; 2005 Jan; 33(1):139-46. PubMed ID: 15470161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: a study with raloxifene, substrate for UGT1A1, 1A8, 1A9, and 1A10.
    Mizuma T
    Int J Pharm; 2009 Aug; 378(1-2):140-1. PubMed ID: 19486934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises.
    Miners JO; Knights KM; Houston JB; Mackenzie PI
    Biochem Pharmacol; 2006 May; 71(11):1531-9. PubMed ID: 16455060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sex-dependent metabolism of xenobiotics.
    Mugford CA; Kedderis GL
    Drug Metab Rev; 1998 Aug; 30(3):441-98. PubMed ID: 9710703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-glucuronidation of drugs and other xenobiotics by human and animal UDP-glucuronosyltransferases.
    Kaivosaari S; Finel M; Koskinen M
    Xenobiotica; 2011 Aug; 41(8):652-69. PubMed ID: 21434773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucuronidation: driving factors and their impact on glucuronide disposition.
    Yang G; Ge S; Singh R; Basu S; Shatzer K; Zen M; Liu J; Tu Y; Zhang C; Wei J; Shi J; Zhu L; Liu Z; Wang Y; Gao S; Hu M
    Drug Metab Rev; 2017 May; 49(2):105-138. PubMed ID: 28266877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of N-glucuronidation of 4-(5-pyridin-4-yl-1H-[1,2,4]triazol-3-yl) pyridine-2-carbonitrile (FYX-051): a new xanthine oxidoreductase inhibitor.
    Omura K; Nakazawa T; Sato T; Iwanaga T; Nagata O
    Drug Metab Dispos; 2007 Dec; 35(12):2143-8. PubMed ID: 17761779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucuronidation of anticancer prodrug PR-104A: species differences, identification of human UDP-glucuronosyltransferases, and implications for therapy.
    Gu Y; Tingle MD; Wilson WR
    J Pharmacol Exp Ther; 2011 Jun; 337(3):692-702. PubMed ID: 21427202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of human UDP-glucuronosyltransferases involved in N-carbamoyl glucuronidation of lorcaserin.
    Sadeque AJ; Usmani KA; Palamar S; Cerny MA; Chen WG
    Drug Metab Dispos; 2012 Apr; 40(4):772-8. PubMed ID: 22259019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.